IL2 and Erythema: One patient (Arm 2, zolbetuximab + ZA + low-dose IL-2) discontinued zolbetuximab because of a treatment-related AE (general deterioration of physical health) and two patients (one patient each in Arms 2 and 3) discontinued from the study because of AEs (deterioration of general physical health and grade 1 erythema).